{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:54:44Z","timestamp":1778525684517,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgar.2021.02.009","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T12:29:33Z","timestamp":1613910573000},"page":"424-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Efficacy and safety of eravacycline: A meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-8637","authenticated-orcid":false,"given":"Khalid","family":"Eljaaly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica K.","family":"Ortwine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Shaikhomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thamer A.","family":"Almangour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.02.009_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/sur.2016.261","article-title":"The Surgical Infection Society revised guidelines on the management of intra-abdominal infection","volume":"18","author":"Mazuski","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.jgar.2021.02.009_bib0010","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/ph6111335","article-title":"A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011","volume":"6","author":"Morrissey","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jgar.2021.02.009_bib0015","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1128\/AAC.00971-12","volume":"57","author":"Sheng","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.02.009_bib0020","series-title":"Xerava\u00ae (eravacycline) for injection, for intravenous use: US prescribing information","author":"Tetraphase","year":"2018"},{"key":"10.1016\/j.jgar.2021.02.009_bib0025","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.06187-11","article-title":"Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic","volume":"56","author":"Grossman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.02.009_bib0030","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/1060028019850173","article-title":"Eravacycline: the tetracyclines strike back","volume":"53","author":"Heaney","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jgar.2021.02.009_bib0035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: a review in complicated intra-abdominal infections","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2021.02.009_bib0040","series-title":"Cochrane handbook for systematic reviews of interventions. Version 5.1.0","article-title":"Chapter 8: Assessing risk of bias in included studies","author":"Higgins","year":"2011"},{"key":"10.1016\/j.jgar.2021.02.009_bib0045","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.02.009_bib0050","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jgar.2021.02.009_bib0055","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.02.009_bib0060","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/21505594.2017.1292196","article-title":"Therapeutic options for carbapenem-resistant Enterobacteriaceae infections","volume":"8","author":"Trecarichi","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.jgar.2021.02.009_bib0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/dku351","article-title":"\u03b2-Lactam\/\u03b2-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials","volume":"70","author":"Shiber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.02.009_bib0070","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jiac.2018.08.004","article-title":"Impact of carbapenem versus non-carbapenem treatment on the rates of superinfection: a meta-analysis of randomized controlled trials","volume":"24","author":"Eljaaly","year":"2018","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2021.02.009_bib0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000440867","article-title":"Acute kidney injury and renal recovery with the use of aminoglycosides: a large retrospective study","volume":"131","author":"Paquette","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.jgar.2021.02.009_bib0080","doi-asserted-by":"crossref","first-page":"ofab026","DOI":"10.1093\/ofid\/ofab026","article-title":"Colistin nephrotoxicity: meta-analysis of randomized controlled trials","volume":"8","author":"Eljaaly","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.02.009_bib0085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-019-1054-3","article-title":"Plazomicin: a novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections","volume":"79","author":"Eljaaly","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2021.02.009_bib0090","series-title":"Tygacil\u00ae (tigecycline): US prescribing information","author":"Wyeth Pharmaceuticals Inc","year":"2010"},{"key":"10.1016\/j.jgar.2021.02.009_bib0095","first-page":"915","article-title":"Impact of requiring re-authorization of restricted antibiotics on day three of therapy","volume":"24","author":"Eljaaly","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.02.009_bib0100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.02.009_bib0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2021.02.009_bib0110","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:54:27Z","timestamp":1761990867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521000412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":22,"alternative-id":["S2213716521000412"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.02.009","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of eravacycline: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}